TIBET PHARMA released its 2024 annual performance, with a net profit attributable to the parent company of 1.051 billion yuan, a year-on-year increase of 31.26%

TIBET PHARMA released its 2024 annual report, with revenue of 2.807 billion yuan, a year-on-year decrease of 10.45%; net profit attributable to shareholders of 1.051 billion yuan, a year-on-year increase of 31.26%; net profit excluding non-recurring items of 859 million yuan, a year-on-year increase of 9.45%; basic earnings per share of 3.26 yuan. The company plans to distribute a cash dividend of 7.28 yuan for every 10 shares to shareholders. The decline in revenue is mainly due to a decrease in sales of new active ingredients, leading to a drop in sales revenue. During the reporting period, the company received industrial support funds of 213.7486 million yuan